Cellular alterations in pituitary tumors

A. Spada, L. Vallar, G. Faglia

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the last few years, molecular studies on pituitary adenomas have yielded evidence supporting a primary pituitary origin of these tumors. Although the existence of genomic alterations in tumoral cells is strongly suggested by the fact that almost all pituitary adenomas are monoclonal in origin, structural genetic abnormalities such as rearrangement, deletion or mutation, which could result in transcriptional activation, have been identified in a minority of tumors. As far as the possible loss of anti- oncogenes in pituitary tumors is concerned, gene alterations have not been found in the p53 nor in the retinoblastoma gene, while loss of chromosome 11q13 sequences, which contain the deduced location of the yet uncloned MEN- 1 gene, has been reported in a subset of GH-secreting adenomas. With regard to the activation of dominant oncogenes in the process of tumor formation, activating mutations of either the Gs α-subunit or the ras gene have been identified in a large proportion of GH-secreting adenomas and in individual particularly invasive tumours, respectively. Promoting agents such as hypothalamic neurohormones and growth factors may be required for the selective growth of genetically altered cells. In this respect, it is worth noting that receptor/postreceptor alterations occurring in pituitary tumors may cause an increased action of stimulatory neurohormones with growth promoting properties as well as defective action of inhibitory inputs.

Original languageEnglish
Pages (from-to)43-52
Number of pages10
JournalEuropean Journal of Endocrinology
Volume130
Issue number1
Publication statusPublished - 1994

Fingerprint

Pituitary Neoplasms
Adenoma
Neurotransmitter Agents
Retinoblastoma Genes
Multiple Endocrine Neoplasia Type 1
Neoplasms
ras Genes
Sequence Deletion
Growth
Tumor Suppressor Genes
Oncogenes
Transcriptional Activation
Genes
Intercellular Signaling Peptides and Proteins
Chromosomes
Mutation

ASJC Scopus subject areas

  • Endocrinology

Cite this

Spada, A., Vallar, L., & Faglia, G. (1994). Cellular alterations in pituitary tumors. European Journal of Endocrinology, 130(1), 43-52.

Cellular alterations in pituitary tumors. / Spada, A.; Vallar, L.; Faglia, G.

In: European Journal of Endocrinology, Vol. 130, No. 1, 1994, p. 43-52.

Research output: Contribution to journalArticle

Spada, A, Vallar, L & Faglia, G 1994, 'Cellular alterations in pituitary tumors', European Journal of Endocrinology, vol. 130, no. 1, pp. 43-52.
Spada A, Vallar L, Faglia G. Cellular alterations in pituitary tumors. European Journal of Endocrinology. 1994;130(1):43-52.
Spada, A. ; Vallar, L. ; Faglia, G. / Cellular alterations in pituitary tumors. In: European Journal of Endocrinology. 1994 ; Vol. 130, No. 1. pp. 43-52.
@article{ad70128313c34031940ae1edbae8a7d3,
title = "Cellular alterations in pituitary tumors",
abstract = "In the last few years, molecular studies on pituitary adenomas have yielded evidence supporting a primary pituitary origin of these tumors. Although the existence of genomic alterations in tumoral cells is strongly suggested by the fact that almost all pituitary adenomas are monoclonal in origin, structural genetic abnormalities such as rearrangement, deletion or mutation, which could result in transcriptional activation, have been identified in a minority of tumors. As far as the possible loss of anti- oncogenes in pituitary tumors is concerned, gene alterations have not been found in the p53 nor in the retinoblastoma gene, while loss of chromosome 11q13 sequences, which contain the deduced location of the yet uncloned MEN- 1 gene, has been reported in a subset of GH-secreting adenomas. With regard to the activation of dominant oncogenes in the process of tumor formation, activating mutations of either the Gs α-subunit or the ras gene have been identified in a large proportion of GH-secreting adenomas and in individual particularly invasive tumours, respectively. Promoting agents such as hypothalamic neurohormones and growth factors may be required for the selective growth of genetically altered cells. In this respect, it is worth noting that receptor/postreceptor alterations occurring in pituitary tumors may cause an increased action of stimulatory neurohormones with growth promoting properties as well as defective action of inhibitory inputs.",
author = "A. Spada and L. Vallar and G. Faglia",
year = "1994",
language = "English",
volume = "130",
pages = "43--52",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Cellular alterations in pituitary tumors

AU - Spada, A.

AU - Vallar, L.

AU - Faglia, G.

PY - 1994

Y1 - 1994

N2 - In the last few years, molecular studies on pituitary adenomas have yielded evidence supporting a primary pituitary origin of these tumors. Although the existence of genomic alterations in tumoral cells is strongly suggested by the fact that almost all pituitary adenomas are monoclonal in origin, structural genetic abnormalities such as rearrangement, deletion or mutation, which could result in transcriptional activation, have been identified in a minority of tumors. As far as the possible loss of anti- oncogenes in pituitary tumors is concerned, gene alterations have not been found in the p53 nor in the retinoblastoma gene, while loss of chromosome 11q13 sequences, which contain the deduced location of the yet uncloned MEN- 1 gene, has been reported in a subset of GH-secreting adenomas. With regard to the activation of dominant oncogenes in the process of tumor formation, activating mutations of either the Gs α-subunit or the ras gene have been identified in a large proportion of GH-secreting adenomas and in individual particularly invasive tumours, respectively. Promoting agents such as hypothalamic neurohormones and growth factors may be required for the selective growth of genetically altered cells. In this respect, it is worth noting that receptor/postreceptor alterations occurring in pituitary tumors may cause an increased action of stimulatory neurohormones with growth promoting properties as well as defective action of inhibitory inputs.

AB - In the last few years, molecular studies on pituitary adenomas have yielded evidence supporting a primary pituitary origin of these tumors. Although the existence of genomic alterations in tumoral cells is strongly suggested by the fact that almost all pituitary adenomas are monoclonal in origin, structural genetic abnormalities such as rearrangement, deletion or mutation, which could result in transcriptional activation, have been identified in a minority of tumors. As far as the possible loss of anti- oncogenes in pituitary tumors is concerned, gene alterations have not been found in the p53 nor in the retinoblastoma gene, while loss of chromosome 11q13 sequences, which contain the deduced location of the yet uncloned MEN- 1 gene, has been reported in a subset of GH-secreting adenomas. With regard to the activation of dominant oncogenes in the process of tumor formation, activating mutations of either the Gs α-subunit or the ras gene have been identified in a large proportion of GH-secreting adenomas and in individual particularly invasive tumours, respectively. Promoting agents such as hypothalamic neurohormones and growth factors may be required for the selective growth of genetically altered cells. In this respect, it is worth noting that receptor/postreceptor alterations occurring in pituitary tumors may cause an increased action of stimulatory neurohormones with growth promoting properties as well as defective action of inhibitory inputs.

UR - http://www.scopus.com/inward/record.url?scp=0028202501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028202501&partnerID=8YFLogxK

M3 - Article

VL - 130

SP - 43

EP - 52

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -